Yes, peptides can affect the liver — but for the best-studied peptide medicines the effect is usually neutral or favorable, with liver injury reported only rarely. For most unregulated research peptides, the honest answer is different: their hepatic safety has simply never been formally studied, so the risk is unknown rather than proven safe.
How the liver handles peptides
Peptides are chains of amino acids, and the body breaks them down the way it breaks down dietary protein: enzymes called peptidases cleave them into fragments and free amino acids. Unlike many small-molecule drugs, most therapeutic peptides are not cleared through the liver's cytochrome P450 enzyme system — the pathway responsible for a large share of classic drug-induced liver injury and drug–drug interactions.
That pharmacology is one reason peptide drugs, as a class, are not prominent causes of hepatotoxicity. It is not a guarantee. Any injected compound can trigger immune reactions, and a peptide that changes appetite, body weight, or metabolism can change liver enzymes indirectly — in either direction.
What approved peptide medicines show in trials
Semaglutide (the GLP-1 receptor agonist in Ozempic and Wegovy) is the most closely watched example, because millions of people use it. The NIH's LiverTox reference — the standard catalog of drug-induced liver injury — reports that in large clinical trials, serum enzyme elevations were no more common with semaglutide than with placebo, and that treatment was usually associated with improvements in aminotransferase (ALT/AST) levels and hepatic steatosis. LiverTox assigns semaglutide a likelihood score of D: a possible but very rare cause of clinically apparent liver injury, based on a small number of post-marketing case reports rather than any signal in trials.
This is what a characterized risk profile looks like: tens of thousands of trial participants, routine liver-panel monitoring, and a pharmacovigilance system that catches even single-digit case counts after launch.
Some peptides are being studied as liver treatments
The relationship can run the other way: fatty liver disease is a major research target for peptide drugs. In a 72-week phase 2 trial in nonalcoholic steatohepatitis (NASH), daily semaglutide 0.4 mg produced NASH resolution in 59% of patients versus 17% on placebo (n=320, NEJM 2021), largely tracking the weight loss it produced. So the question "do peptides affect the liver" has a genuinely two-sided answer: the best-evidenced effects of GLP-1 peptides on the liver are beneficial ones.
How liver safety is monitored in trials and practice
Formal drug development watches a standard set of hepatic signals:
- ALT and AST (aminotransferases) — enzymes released when liver cells are injured.
- Alkaline phosphatase and bilirubin — markers of bile-flow problems and overall liver function.
- Combined patterns — a rising ALT together with rising bilirubin ("Hy's law" cases) is the red flag regulators treat most seriously.
Trial protocols check these at baseline and on a schedule, exclude or stratify people with significant pre-existing liver disease, and report abnormalities in the label. That monitoring infrastructure is precisely what does not exist around gray-market peptide use.
The evidence gap for research peptides
For compounds like BPC-157, AOD-9604, or 5-amino-1MQ, there are no large human trials, no liver-panel datasets, and no post-marketing surveillance. When the FDA reviewed several of these substances for compounding, it concluded it had "no, or only limited, safety-related information" for compounds including BPC-157 — along with concerns about peptide-related impurities and immunogenicity. An absence of reported liver injury from a compound nobody has systematically monitored is not evidence of hepatic safety; it is evidence of an unmonitored compound.
Product quality adds a second, separate hazard: an unregulated vial can contain the wrong dose, residual synthesis impurities, or contaminants — exposures that have nothing to do with the peptide's own biology but still reach the liver.